The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021.

Autor:	Cheung TT; Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China., Yu SC; Department of Imaging & Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China., Chan SL; State Key Laboratory of Translational Oncology and Department of Clinical Oncology, Sir YK Pao Centre for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China., Poon RTP; Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China., Kwok P; Department of Radiology and Imaging, Queen Elizabeth Hospital, Hong Kong, China., Lee AS; Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China., Tai A; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China., Tam D; Department of Surgery, United Christian Hospital, Hong Kong, China., Cheung CC; Department of Surgery, Tuen Mun Hospital, Hong Kong, China., Lai TW; Department of Surgery, Princess Margaret Hospital, Hong Kong, China., Chia NH; Department of Surgery, Queen Elizabeth Hospital, Hong Kong, China., Law A; Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China., Shum T; Department of Clinical Oncology, Princess Margaret Hospital, Hong Kong, China., Lam YK; Department of Medicine and Geriatrics, United Christian Hospital, Hong Kong, China., Lau V; Department of Radiology, Queen Mary Hospital, Hong Kong, China., Lee V; Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China., Chong C; Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China., Tang CN; Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China., Yau T; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Jazyk:	angličtina
Zdroj:	Hepatobiliary surgery and nutrition [Hepatobiliary Surg Nutr] 2023 Jun 01; Vol. 12 (3), pp. 366-385. Date of Electronic Publication: 2023 May 06.
DOI:	10.21037/hbsn-21-405
Abstrakt:	Background and Objective: Hong Kong, like many parts of Asia, faces a high burden of hepatocellular carcinoma (HCC) caused by high endemic rates of hepatitis B virus infection. Hong Kong clinicians have developed a high level of expertise in HCC treatment across surgical, transarterial, ablative, radiotherapeutic and systemic modalities. This publication summarizes the latest evidence-based recommendations on how these modalities should be used. Methods: In two meetings held in 2020, a multidisciplinary panel of surgeons, oncologists and interventional radiologists performed a narrative review of evidence on the management of HCC, with an emphasis on treatment of HCC not amenable to surgical resection. Close attention was paid to new evidence published since the previous version of these statements in 2018. Key Content and Findings: The expert panel has formulated 60 consensus statements to guide the staging and treatment of unresectable HCC. Since the previous version of these statements, considerable additions have been made to the recommendations on use of targeted therapies and immunotherapies because of the large volume of new evidence. Conclusions: Our consensus statements offer guidance on how to select HCC patients for surgical or non-surgical treatment and for choosing among non-surgical modalities for patients who are not candidates for resection. In particular, there is a need for more evidence to aid physicians in the selection of second-line systemic therapies, as currently most data are limited to patients with disease progression on first-line sorafenib. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-21-405/coif). TTC has received research funding from Eisai for medical writing and for funding support to an investigator-initiated study, and study support from BMS for provision of drug to an investigator-initiated study. SC has received research grants from Bayer, MSD, Eisai, Sirtex, and Ipsen, consulting fees from Novartis, MSD, Eisai, AstraZeneca, and Bristol Myers Squibb, and speaking honoraria from Bayer, Astra-Zeneca, Eisai, Roche, and MSD. TY has received research funding from Bayer, Eisai and Ipsen and speaking honoraria from Bristol Myers Squibb, Eisai, Ipsen, MSD, AstraZeneca, and Bayer. The other authors have no conflicts of interest to disclose. (2023 Hepatobiliary Surgery and Nutrition. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu